论文部分内容阅读
目的 探讨肝病患者抗氧化能力 (TAO)及一氧化氮合酶 (NOS)表达的临床价值。方法 收集急性肝炎 (AH)、慢性肝炎 (CH)、肝硬化 (LC)及肝癌 (HCC)患者血清 ,分别检测其TAO、NOS浓度及NO水平 ,分析它们在肝脏疾病中的改变机制。结果 患者血清TAO在AH、CH中异常率占 80 % ,在LC和HCC为 50 % ;血清中NOS活性在肝病患者中的异常率在 70 %左右 ;NO水平在AH、CH和LC中异常率为 70 % ,HCC组为 4 8%。AH组、CH组TAO平均水平明显高于对照组 ,但LC和HCC组的差异不明显 ;肝病患者NO和NOS平均浓度均非常明显高于对照组 ,但HCC患者NOS和NO平均浓度均低于AH、CH和LC组患者。结论 肝病患者血NOS水平与NO浓度呈高度正相关 ,NO增加可能对肝细胞起保护作用。
Objective To investigate the clinical value of antioxidant capacity (TAO) and nitric oxide synthase (NOS) expression in patients with liver disease. Methods The serum of patients with acute hepatitis (AH), chronic hepatitis (CH), liver cirrhosis (LC) and hepatocellular carcinoma (HCC) was collected and their TAO, NOS and NO levels were measured respectively. Results The abnormal rate of TAO in AH, CH was 80% in patients and 50% in LC and HCC. The abnormal rate of serum NOS activity was about 70% in patients with liver disease. The abnormal rate of NO in AH, CH and LC 70%, HCC group 48%. The average level of TAO in AH group and CH group was significantly higher than that in control group, but the difference between LC and HCC group was not obvious. The average concentrations of NO and NOS in patients with liver disease were significantly higher than those in control group, but the average concentrations of NOS and NO in HCC patients were lower than AH, CH and LC patients. Conclusion There is a highly positive correlation between serum NOS level and NO concentration in patients with liver disease. Increased NO may play a protective role on hepatocytes.